Continental Advisors LLC Sells 11,500 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Continental Advisors LLC reduced its holdings in Gilead Sciences by 20.4%, selling 11,500 shares and now owning 44,867 shares valued at approximately $5 million.
• Gilead Sciences reported $2.01 earnings per share for the last quarter, exceeding the consensus estimate and showing a 1.4% year-over-year revenue increase.
• The company declared a quarterly dividend of $0.79 per share, with an annualized yield of 2.7%, payable to shareholders on September 29th.

Continental Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,867 shares of the biopharmaceutical company's stock after selling 11,500 shares during the quarter. Gilead Sciences comprises approximately 2.8% of Continental Advisors LLC's portfolio, making the stock its 13th biggest holding. Continental Advisors LLC's holdings in Gilead Sciences were worth $5,027,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the 1st quarter valued at $25,000. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors increased its holdings in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital increased its holdings in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.7%

GILD opened at $115.88 on Tuesday. The stock has a market cap of $143.79 billion, a PE ratio of 23.08, a P/E/G ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $78.36 and a 52 week high of $121.83. The business's fifty day simple moving average is $113.69 and its 200 day simple moving average is $109.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the business posted $2.01 earnings per share. The company's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,371,330. Corporate insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.